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Association of ACE gene polymorphism and diabetic
nephropathy?
SUSANNE SCHMIDT, NINA SCHONE, EBERHARD RITZ, and THE DIABETIC NEPHROPATHY STUDY GROUP'
Department of Intermal Medicine, Ruperto Carola University Heidelbeiy, Germany
Association of ACE gene polymorphism and diabetic nephropathy. In
patients with type 1 diabetes an association has been found between an
insertion/deletion (I/D) polymorphism in the gene for angiotensin I
converting enzyme and the presence of diabetic nephropathy. Our objec-
tive was (i) to assess this association in a large cohort of patients with type
1 diabetes and (ii) to examine whether this finding also applies to type 2
diabetes. We examined 247 patients with type 1 diabetes of more than 10
years duration (135 patients  20 years): Nephropathy was present in 114
and absent in 133 patients. Furthermore we separately analyzed 455
patients with type 2 diabetes of more than 10 years duration (158 patients
 20 years). Nephropathy was present in 247 and absent in 208 patients.
Nephropathy was defined by confirmed presence of albuminuria > 30
mg/day (or> 20 j.g1min). The I/D polymorphism was analyzed with PCR
technique and alleles were visualized on 2% agarose gels after ethidium
staining. Allele frequencies in the overall diabetic population did not differ
significantly from the normal population. Distribution of genotypes was
not significantly different between type 1 patients with and without
nephropathy (P = 0.377). Also, no significant difference in genotype
distribution was found between type 2 diabetic patients with and without
nephropathy (P = 0.948).
We conclude that no significant association between I/D polymorphism
and nephropathy was demonstrable in either type 1 or type 2 diabetes,
despite considerable statistical power of the patient sample and adequate
duration of diabetes for nephropathy to become manifest.
Nephropathy is a frequent complication of long term diabetes.
Good evidence exists that genetic predisposition plays a major
role in development of diabetic nephropathy [1, 2]. This hypoth-
esis is based on the observation that diabetic nephropathy clusters
within families, both in type 1 (IDDM) [1] and type 2 (NIDDM)
diabetes [2].
The gene(s) responsible for genetic predisposition to diabetic
nephropathy is (are) not known, but the genes of the renin-
angiotensin systems are plausible candidate genes. Their encoded
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proteins are involved not only in regulation of systemic blood
pressure, but also in the regulation of intrarenal hemodynamics.
Angiotensin I converting enzyme (ACE) plays a key role in the
enzymatic cascade that generates the vasoactive peptide angioten-
sin II (Ang II). A role of Ang II in progression of renal disease has
been postulated [3]. It has also been shown that serum ACE
activity is elevated in some diabetic subjects [4], particularly in
subjects with type 1 diabetes and microalbuminuria [5]. Serum
and tissue ACE levels are under control of an insertion/deletion
(lID) polymorphism of the ACE gene, which is located in intron
16 [6, 71. This polymorphism has been shown to be associated with
the risk of myocardial infarction [8], cardiomyopathy [9] and left
ventricular hypertrophy [10]. The hypothesis has been advanced
that local availability of Ang II in tissues is under the control of
this polymorphism.
Recently Marre et al [11] reported that in patients with type 1
or insulin dependent diabetes mellitus (IDDM) the lID polymor-
phism in the ACE gene is related to the presence of nephropathy.
The aim of the present study was (i) to confirm or refute this
association and (ii) to examine whether the association applies to
type 2 or non-insulin dependent diabetes mellitus (NIDDM) as
well.
Methods
Patients
Diabetic patients were recruited from the outpatient clinic in
Heidelberg and four German (Bad Mergentheim, Bad Lauter-
berg, Bad Oeynhausen, Quakenbrück) and one Polish (Zabrze)
diabetes clinics. Furthermore, diabetic patients with dialysis-
dependent diabetic nephropathy were recruited from the dialysis
centers of Heidelberg, Weinheim, Worms, Heilbronn and Mann-
heim. All patients gave their written informed consent. The study
was approved by the local Ethics Committee.
An obligatory inclusion criterion was known duration of diabe-
tes for at least 10 years. Classification of diabetes was made
according to the National Diabetes Data Grnup criteria [12, 131.
Patients with maturity onset diabetes of the young (MODY) were
excluded from the study. The diagnosis of nephropathy was based
on confirmed (on at least three consecutiv.e occasions) urinary
albumin excretion above 30 mg/24 hr or 20-igImin as a minimum
criterion (in non-oliguric patients) with or without elevated serum
creatinine, and hypertension (or dialysis dependency). Secondary
causes of albumin excretion were excluded by appropriate clinical
investigations. Information on cardiac events was obtained by
questionnaire. To exclude the presence of other primary chronic
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Table 1. Characteristics of the patient sample
Typel Type2
Without WithWithout With
nephropathy nephropathy nephropathy nephropathy(N = 133) (N = 114) (N = 208) (N = 247)
Genderflm 58/75 43/71 127/81 128/119
Age years
Body mass index kg/rn2
44 15.4
25.1 3.5
45 15.5
25.1 3.8
63 9.7
28.9 4.5
65 9.3
28.5 5.1
Known duration of diabetes years 20.7 8.5 22.7 9.1 16.7 6.8 18.0 6.3
Proportion of diabetes a20 years 65/133 70/114 59/208 99/247
Data are means and SD.
Table 2. Clinical findings
Typel
Without
nephropathy(N = 133)
With
nephropathy(N = 114)
Type2
Without
nephropathy(N = 208)
With
nephropathy(N = 247)
HbAle % 8.3 1.3 8.1 1.8 8.8 1.8 8.8 1.9
Dialysis dependency — 26/114 — 54/247
Hypertension5 38/133 70/114 133/208 188/247
Retinopathy
background 68/133 58/114 49/208 81/247
proliferative
Cardiac eventsb
17/1 33
9/133
27/114
20/114
9/208
39/208
37/247
86/247
Serum creatinine mg/dlc 0.8 0,2 1.1 0.7 0.8 0.2 1.2 0.9
Data are means and SD.
Casual BP 140/90 mm Hg or antihypertensive treatmentbJachemic cardiomyopathy and/or congestive heart failure
In non-dialysis dependant patients
renal disease, participating centers were asked to perform ultra-
sonography and to exclude patients with a histoiy of renal disease
or urinary findings other than isolated albuminuria/proteinuria.
From each patient 20 ml blood was drawn: 10 ml EDTA blood
for DNA isolation and 10 ml blood for serum ACE activity
determination.
In addition DNA from 134 individuals (mean age 35 years
8.7, sex: m = 87/f = 47) of the local blood bank was analyzed to
determine allele frequencies in the normal population.
Senm ACE determination
ACE activity was determined in patients without ACE inhibitor
treatment using a colorimetric assay (Fujirebio, Inc./Mast Diag-
nostica, Germany). ACE cleaves the substrate in p-hydroxyben-
zoylglycine and L-histidine-L-leucine. p-Hydroxybenzoylglycine is
cleaved by hippuricase from substrate buffer in p-hydroxybenzoic
acid and glycine. In an oxidation and condensation step the
colored complex chinonimine is formed, which is quantitated
spectrophotometrically at 505 nm (492 nm).
Polymerase chain reaction
ACE genotypes were determined using the polymerase chain
reaction (PCR) technique [14]. DNA was isolated from peripheral
leukocytes following a combined salting out-protocol according to
Graham [15] and Miller, Dykes and Polesky [16].
For the amplification reaction we used alternative primers (we
thank Dr. K. Lindpaintner, Harvard Medical School, Boston for
providing the sequence information):
5 '-GCCCTGCAGGTGTCTGCAG-
CATGT-3'
5 '-GGATGGCTCTCCCCGCCT-
TCTCTC-3'
These primers have higher fidelity in amplifying the polymorphic
region than the ones reported before [14]. To enhance genotyping
and to prevent misclassification of heterozygous individuals we
added 5% dimethylsulfoxide (DMSO) to the reaction mixture
[17].
Statistical analysis
Data are given as mean and standard deviation (SD). Genotype
distributions and allele frequencies were compared between
groups using the test.
Results
Characteristics of the patient sample and clinical findings
The groups of type 1 and type 2 diabetic patients without and
with diabetic nephropathy, respectively, were comparable with
regard to age, body mass index (BMI) and (known) duration of
diabetes (Table 1).
Table 2 shows the relevant clinical findings. Patients with either
type 1 or type 2 diabetes who had nephropathy were significantly
more often hypertensive and had more frequently reports on
cardiac events (ischemic cardiomyopathy and/or congestive heart
failure). As expected they had also a higher prevalence of diabetic
retinopathy, particularly of the proliferative type.
sense-oligo:
antisense-oligo:
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Table 3A. Genotype distribution in the overall patient cohort
Type 1 Type 2
Without With Without With
nephropathy nephropathy nephropathy nephropathy
Genotype (N = 133) (N = 114) (N = 208) (N = 247)
DD 55 52 83 101
ID 55 38 91 105
II 23 24 34
Type 1: P = 0.377: Type 2: P = 0.948
Table 3B. Genotype distribution in patients with known duration of diabetes 20 years
41
Type 1
Without With Without
nephropathy nephropathy nephropathy
Type 2
With
nephropathy
Genotype (N = 65) (N = 70) (N = 59) (N = 99)
DD 24 32 31 45
ID 25 15 24 39
II 16 13 4
Type 1: P = 0.53 Type 2: P = 0.279
Table 4. Allele frequencies in the overall patient cohort
15
Controls
Type 1
Without With Without
nephropathy nephropathy nephropathy
Type 2
With
nephropathy(N = 134) (N 133) (N = 114) (N = 208) (N = 247)
D 0.6 0.62 0.62 0.62 0.62
I 0.4 0.38 0.38 0.38 0.38
There were no significant differences between groups.
In patients not treated with ACE inhibitors serum ACE levels
were correlated with genotype as reported by Tiret et al [18].
Individuals of the DD genotype had the highest serum ACE levels
(14.4 5.5 mU/mi), II genotype the lowest levels (12.4 6.3
mU/ml) and the values of heterozygotes were in between (13.4
4.4 mU/ml).
Findings in patients with type 1 diabetes
Genotype distribution was not significantly different between
patients with and without nephropathy after at least 10 years
duration of diabetes (Table 3A). This was the primary endpoint of
the study. Even when more stringent inclusion criteria were
applied, in post-hoc analysis on subsamples considering only
patients with diabetes 20 years to maximize the chance that
diabetic nephropathy had developed [19], genotype distribution
was not significantly different between patients with and without
nephropathy (Table 3B). Using allele frequencies found in this
study genotype distributions were in Hardy-Weinberg equilibrium
in both groups, documenting that the gene and genotype frequen-
cies did not deviate significantly from the equilibrium predicted by
the law of Mendel in a random mating population.
No significant difference of genotype distribution was noted
between nonalbuminuric patients (N = 133) and patients with
albuminuria plus retinopathy (N = 85) or dialysis dependent
patients (N 26).
Allele frequencies did not differ between diabetic patients with
and without nephropathy and they were also not significantly
different from the allele frequencies determined in the control
population (N = 134; D 0.6; I 0.4; DD 49; ID 63; II 22; Table 4).
Findings in patients with type 2 diabetes
Genotype distribution and allele frequencies were also com-
pared between type 2 diabetic patients with and without nephrop-
athy. No statistically significant difference was observed between
diabetic patients with and without nephropathy as the primary
endpoint. In post-hoc subsample analysis in patients with known
diabetes duration of at least 10 years (Table 3A) or with the more
stringent criterion of (known) diabetes duration of at least 20
years (Table 3B), no significant difference was found either.
Genotype distributions in both groups were in Hardy-Weinberg
equilibrium.
No significant difference was noted between nonalbuminuric
patients (N = 208) and patients with albuminuria plus retinopathy(N = 118); II homozygotes were less frequently found in dialysis
dependent patients (3 of 54) than in nonalbuminuric patients (34
of 208). By 2 test the difference reached P < 0.05, but this level
was not significant after Bonferroni correction.
Allele frequencies were not significantly different between the
two groups of type 2 diabetic patients and did not significantly
deviate from the frequency in the control population (Table 4).
Discussion
In a recent paper Marre et al [11] reported on a low proportion
of individuals homozygous for the II genotype in type 1 diabetic
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patients with nephropathy compared to patients without nephrop-
athy. The authors cautioned that the data were obtained in white
French subjects and additional studies in other ethnic or national
groups were required. It was the purpose of the present study to
address this issue.
In designing the study we made the assumption that albumin-
uria was a valid index of glomerular lesions and renal prognosis, a
tenet that is widely accepted by most, but not all [20] investigators.
It has also been noted that some diabetic patients have consider-
able glomerular lesions by morphology despite no albuminuria
[21]. Moreover, particularly in individuals with type 2 diabetes,
albuminuria may be present for reasons other than diabetic
nephropathy, such as congestive heart failure, urinary tract infec-
tion or superimposed primary chronic glomerulonephritis [22, 23].
We tried to exclude these possibilities by clinical examination, but
we cannot exclude that some patients were erroneously included
in the group with nephropathy. In view of such potential con-
founders, however, in addition we separately analyzed patients
meeting more stringent criteria, for example, patients with albu-
minuria plus retinopathy or with dialysis dependence, keeping in
mind the Bonferroni problem of repetitive testing.
It has been assumed that ACE polymorphism correlates with
tissue ACE levels and thus determines local availability of Ang TI
[24]. If different glomerular Ang II levels were the mechanism
underlying the above association [11], one might suspect that Ang
II is equally pathogenetic in type I and type 2 diabetes and that
the association should also be present in type 2 diabetes. This
consideration provided the rationale to study patients with type 2
diabetes as well.
Another consideration relates to the statistical power of the
study. The importance of sample size is illustrated by our experi-
ence: we noted a significant difference during an interim analysis
when the number of patients with type 1 diabetes was 35 per
group [25]. The significant difference vanished when the sample
size grew larger. The patient sample of Marre et al [11] of 62
patients per group had sufficient power (80%) to detect a 20%
deviation of II genotype frequency with P < 0.05. Beta-error
analysis shows that such deviation could even be picked up
examining 49 individuals per group. On the other hand our
cohorts were sufficiently large to yield 75% power to detect even
a 10% deviation with P < 0.05, and had >95% power to detect a
20% deviation. The negative finding is thus definitely not ex-
plained by insufficient statistical power.
The cohorts of patients with type 1 and type 2 diabetes with and
without nephropathy were comparable to samples reported in
literature [19, 23] with respect to age, distribution of genders and
duration of diabetes. This makes selection bias unlikely and
suggests that we examined a representative patient sample.
The salient result of the present study is the finding that an
association between lID polymorphism and presence or absence
of diabetic nephropathy could not be established either in type 1
diabetes or in type 2 diabetes. This had been the primary endpoint
of the present study. In an effort to generate hypotheses we also
carried out subsample analysis, keeping in mind the biostatistical
limitations of this approach. Nevertheless, when analysis was
restricted to patients meeting more stringent criteria of nephrop-
athy, such as combination of albuminuria and retinopathy or
dialysis dependency, no significant trend emerged.
We considered a number of methodological problems. An
effort was made to increase the sensitivity of the method by
adopting the procedure of Shanmugan, Sell and Saha [17], since
the original method may occasionally lead to misclassification of
heterozygotes (lID).
No major variation of l/D allele frequencies has been found
between different ethnic groups [6, 9, 26, 27]. Nevertheless,
because patients were recruited from widely different geographic
areas, we looked at allele frequencies in the different populations.
As anticipated no significant differences were found. In addition,
Hardy-Weinberg equilibrium was noted in the overall population
and in all subsamples. We emphasize that only Caucasoids were
examined in this study.
An important question is whether diabetic individuals may have
been misclassified as having no nephropathy because duration of
diabetes was insufficient for diabetic nephropathy to become
manifest. According to Krolewski et al [19] the overwhelming
majority of patients with type 1 diabetes who will ultimately
develop diabetic nephropathy will have done so by 20 years after
onset of diabetes. We carried out a separate post-hoc analysis
considering only patients with or without albuminuria and dura-
tion of diabetes exceeding 20 years, but again the results were
negative. The issue is more complex in type 2 diabetes where
manifest diabetes may be preceded by long periods of unrecog-
nized hyperglycemia. If anything, however, this should underesti-
mate the true duration of diabetes and increase the probability for
diabetic nephropathy to become manifest. In contrast to previous
opinion recent studies indicate that the renal risk is similar in type
1 and type 2 diabetes [28].
Classification of type 1 and type 2 diabetes was done according
to the criteria of the National Diabetes Data Group [12, 13]. We
are aware of the possibility that some individuals with type 2
diabetes according to these criteria may exhibit islet cell antibod-
ies [29] and/or initially low C-peptide levels. Because the overall
result was negative we did not perform in depth analyses to
exclude this artifact. An effort was also made to exclude individ-
uals who satisfied the criteria of MODY (maturity onset diabetes
of the young), because of recent recognition that this group of
individuals has a specific molecular pathogenesis [30]. Most likely,
in the remaining patients with type 2 diabetes molecular patho-
genesis will be quite heterogeneous as well.
Since the ACE gene polymorphism is a predictor of cardiac
death [24] we entertained the possibility that high risk DD
patients were selectively lost as a result of high cardiovascular
mortality. This mechanism presumably did not distort allele
frequencies, since they were similar in individuals without albu-
minuria and low cardiac risk [31] and in individuals with albumin-
uria and high cardiac risk.
What are the implications of this study?
There are many reasons to implicate the renin system as a
player in the genesis of diabetic nephropathy. Although renin
activity (PRA) is consistently low in patients with diabetes mdli-
tus [32], the level of PRA may be inappropriate to the known
expansion of sodium space [33, 34]. A further potential argument
for a role of the renin system is the observation that in diabetic
patients the pressor action of angiotensin II (Ang II) is increased
[35] and that platelet Ang binding sites are inappropriatly high in
relation to circulating Ang II [36, 37]. Increased prorenin concen-
trations in patients with diabetic microangiopathy [38, 39] argue
for increased transcription of the renin gene, although this does
not necessarily imply increased secretion of active renal renin [391.
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In several tissues including the kidney considerable compartmen-
tation of Ang II has been noted. Although ACE in the systemic
circulation is not rate limiting for the generation of Ang II [40] it
may well be so in tissue compartments [8]. Indeed, since the
genetically coded ACE isoenzymes are differently expressed on
lymphocytes [7] as potential indicator cells, it has been speculated
that the ACE gene polymorphism was a determinant of tissue
ACE activity. This led to the speculation that differences in tissue
ACE activity determine different local concentrations of active
Ang II.
While the above observation tends to exclude genetically de-
termined differences in ACE as an important factor in the genesis
of diabetic nephropathy, the overall role of the refill system is
certainly by no means excluded by the above negative result.
In conclusion, no significant association was demonstrable
between lID polymorphism and nephropathy either in type 1 or
type 2 diabetes when we examined cohorts of sufficient size to
provide high statistical power and of sufficient duration of diabe-
tes to maximize the chance that diabetic nephropathy had become
manifest.
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